FRANKFURT (Reuters) - Merck KGaA's Cilengitide, an experimental drug to treat an aggressive type of brain tumor, has failed a large-scale clinical trial, dealing a blow to the German drugmaker's efforts to replenish its pipeline of medicines.
Source: http://feeds.reuters.com/~r/reuters/healthNews/~3/OS9bpMUyIxw/us-merck-phaseiii-idUSBRE91O0BS20130225
phlebotomy training in maine chiropody courses phlebotomy courses in toronto
No comments:
Post a Comment